Fundraise

Mediintech raises $25.3M Series C to build surgical robots

What's the deal? Mediintech, a South Korean medical robotics startup, has raised US$28.3M in a Series C round to expand from diagnostic endoscopy into treatment and surgical robots. Atinum InvestmentDealroom has a profile for this one. Try Dealroom → and KB InvestmentDealroom has a profile for this one. Try Dealroom → co-led the round.

Who else joined? Returning backers Smilegate InvestmentDealroom has a profile for this one. Try Dealroom →, SL InvestmentDealroom has a profile for this one. Try Dealroom →, ICF (Nextrans)Dealroom has a profile for this one. Try Dealroom →, and Wooshin Venture InvestmentDealroom has a profile for this one. Try Dealroom → followed on, while K2 Investment PartnersDealroom has a profile for this one. Try Dealroom → came in as a new investor. The company plans to close the round after securing additional investment within the year.

What does it do? Mediintech, founded in 2020, makes an AI-powered robotic endoscope called INTION S. It replaces the manual wire-pull controls of standard endoscopes with motor-based precision control, and adds autonomous steering that links what its AI detects to the device's movement.

A trial of 178 adults at Seoul National University Hospital found the system non-inferior to mechanical endoscopes on key handling measures while cutting physician fatigue. The results appeared in Scientific Reports .

What's the endgame? The money will fund next-generation surgical robots that use Mediintech's robotic drive and precision-control technology. It will also diversify its endoscope lineup and invest in R&D staff, prototypes, regulatory approvals, and mass production.

The company has lined up commercial traction: it supplied INTION S to Korea's National Fire Service Hospital and Ajou University Hospital through a distribution deal, and began early sales in Thailand, the Philippines, and Mongolia. It also sells INTION DEEPEYE, software that flags abnormalities in stomach and colon endoscopy images.

By the numbers: Mediintech raised US$6.71M in a 2022 Series A and US$16.8M in a 2024 Series B, bringing cumulative funding to roughly US$52.1M. A separate US$19.1M government medical-device R&D project, selected in April, will support development of autonomous steering and miniature multi-joint instruments.

What could go wrong? Moving from diagnostic endoscopes to surgical robots means a steeper bar for clinical validation and regulatory approval. The field is crowded: Intuitive Surgical reported roughly 15% procedure growth in the third quarter of 2026, and Medtronic's Hugo robot is broadening its US clearances. Funding alone does not prove clinical or commercial success in surgery.

The signal: Investors are betting that AI-driven endoscopy is becoming a bridge into the surgical robot market, where demand is expanding. "This Series C will be an important opportunity to prepare for the next growth stage," said chief executive officer Lee Chi-won, pointing to a platform spanning "diagnosis to treatment and surgery."

Read more: venturesquare.net

Image credit: Mediintech

More top stories